Innovative Medicine
-
-
ASH 2016: Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab and Other Compounds Showing Treatment Advances in Malignant and Non-Malignant Hematologic Conditions
Key data include Phase 2 five-year follow-up data for ibrutinib in CLL and updated Phase 3 depth of response data for daratumumab in combination with standard of care therapies for patients with multiple myeloma who have received at least one prior therapy -
Janssen to Present Data Across Broad Rheumatology Portfolio and Immunology Pipeline at the 2016 American College of Rheumatology Meeting
Twenty-Eight Janssen Data Presentations Demonstrate Commitment to Innovation in Rheumatology -
Janssen Partners with University of Pennsylvania and Castleman Disease Collaborative Network to Launch First Global Patient Registry for Castleman Disease
Registry Aims to Improve Care and Accelerate Research for Rare Disorder by Putting Power in the Hands of Patients -
Janssen Therapeutics Announces Funding in Support of Improved Retention in Care and Access to Treatment for Blacks and African Americans Living with HIV in Southern United States and other Rural Areas
Award Funding Extends Company’s Ongoing Commitment to Supporting Underserved Communities in the United States -
-
U.S. FDA Approves Vermox™ Chewable (Mebendazole) For Treatment of Children and Adults With Roundworm and Whipworm Infections
New tablet formulation provides alternative treatment for millions of children around the world infected by intestinal worms -
Ibrutinib (IMBRUVICA®) Supplemental New Drug Application Submitted to the U.S. Food and Drug Administration (FDA) for Marginal Zone Lymphoma (MZL)
Latest submission seeks marketing approval for fifth unique indication. No therapies currently approved for the treatment of patients with marginal zone lymphoma, a rare and incurable disease -